Key Highlights

  • Dermata Therapeutics, Inc. (NASDAQ:DRMA) traded at USD 0.7595, down 13.17%, in pre-market trading on Thursday, October 29, 2026, and no company-specific announcement dated Wednesday, October 28, 2026 or Thursday, October 29, 2026 was identified.
  • The company's release of Thursday, October 15, 2026 reported topline results of an open-label cosmetic study of its Tome Foundational Treatment in 31 participants, and the shares rose 37.19% on that day, according to market data.
  • In the second quarter of 2026 the company reported a net loss of USD 3.0 million, or USD 0.74 per share, and cash of USD 4.4 million at June 30, 2026, in its release of Tuesday, August 11, 2026.
  • The company announced about USD 3.4 million of gross proceeds from a private placement at USD 1.46 per share on Monday, August 17, 2026, and the pre-market quote is a thinly traded snapshot that can change at the 9:30 a.m. ET open.

The Pre-Market Move and Its Catalyst

Dermata Therapeutics, Inc. (NASDAQ:DRMA), a clinical-stage company developing topical treatments for skin conditions, traded at USD 0.7595, down 13.17%, in pre-market trading on Thursday, October 29, 2026, according to a pre-market snapshot. No company-specific announcement dated Wednesday, October 28, 2026 or Thursday, October 29, 2026 accompanied the move. The nearest catalyst is the company's release of Thursday, October 15, 2026 on an open-label cosmetic study of its Tome Foundational Treatment, applied once weekly for four weeks by 31 participants. In the study 93% agreed the treatment was comparable to a professional in-office procedure, 90% saw more noticeable results than with other products and no treatment-related adverse events were reported. The fall appears consistent with a partial giveback of the gain of October 15 in thin liquidity.

How the Cash Position and Financing Frame the Move

Dermata Therapeutics, Inc. (NASDAQ:DRMA) reported in its release of Tuesday, August 11, 2026 a second quarter net loss of USD 3.0 million, or USD 0.74 per share, and cash of USD 4.4 million at June 30, 2026. The company announced on Monday, August 17, 2026 a private placement with about USD 3.4 million of gross proceeds at USD 1.46 per share, and up to about USD 6.7 million more if warrants are exercised for cash. Cash plus the gross proceeds is about USD 7.8 million, or about 2.6 times the second quarter loss, on simple arithmetic before fees and later spending. An earlier placement of Monday, December 29, 2025 priced shares at USD 2.04. Market data show a market capitalisation of about USD 4.3 million at a close of USD 0.86.

Risks and What to Watch

The bull reading for Dermata Therapeutics, Inc. (NASDAQ:DRMA) is that the cosmetic study gives a consumer-oriented use for its technology, with favourable participant ratings and no treatment-related adverse events, and that warrant exercises could add up to about USD 6.7 million. The bear reading is that the study was open-label with only 31 participants, the quote is about 48% below the August placement price on simple arithmetic and the company reports recurring losses. Named risks include dilution from further financing, a possible Nasdaq minimum bid price deficiency (an inference given a quote under USD 1.00) and thin liquidity. Investors should watch the third quarter results, any financing or listing notice and the 9:30 a.m. ET open on Thursday, October 29, 2026.

Where Things Stand

The answer is that Dermata Therapeutics, Inc. (NASDAQ:DRMA) fell 13.17% pre-market on Thursday, October 29, 2026, which appears consistent with a partial giveback of the 37.19% gain that followed the cosmetic study of Thursday, October 15, 2026. The key number is cash of USD 4.4 million at June 30, 2026 against a quarterly net loss of USD 3.0 million. The next catalysts are the third quarter results, any financing or listing notice and the 9:30 a.m. ET open on Thursday, October 29, 2026. Pre-market prices are snapshots and can change, and this is not investment advice.